Certara

OverviewSuggest Edit

Certara is a biotech company engaged in the drug development process. It provides modeling and simulation software as well as regulatory writing, submission managing, and consulting services to the biotechnology, pharmaceutical, and other life science enterprises.
TypePublic
Founded2008
HQPrinceton, NJ, US
Websitecertara.com
Employee Ratings4.1

Latest Updates

Employees (est.) (Dec 2021)1,054(+25%)
Job Openings318
Revenue (FY, 2021)$286.1 M(+18%)
Share Price (May 2022)$19.3(+4%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Certara

William Feehery

William Feehery

Chief Executive Officer, Director
Steve Sibley

Steve Sibley

Vice President, Synchrogenix Regulatory Science
Diana O'Rourke

Diana O'Rourke

Chief Strategy and Marketing Officer
Robert Aspbury

Robert Aspbury

President, Simcyp
Mark Bowlby

Mark Bowlby

Director, Global Submissions
Jieun W. Choe

Jieun W. Choe

Chief Strategy and Marketing Officer
Show more

Certara Office Locations

Certara has offices in Princeton, Cincinnati, Clayton, Jenkintown and in 26 other locations
Princeton, NJ, US (HQ)
100 Overlook Center #101
Cincinnati, OH, US
9436 Waterstone Blvd #100
Clayton, MO, US
222 S Central Ave #1008
Jenkintown, PA, US
165 Township Line Rd #100
Malvern, PA, US
5 Great Valley Pkwy #356
Menlo Park, CA, US
4200 Bohannon Dr #280
Show all (30)

Certara Financials and Metrics

Certara Revenue

Embed Graph
View revenue for all periods
Certara's revenue was reported to be $286.1 m in FY, 2021 which is a 17% increase from the previous period.
USD

Revenue (FY, 2021)

286.1m

Revenue growth (FY, 2020 - FY, 2021), %

17%

Gross profit (FY, 2021)

174.5m

Gross profit margin (FY, 2021), %

61%

Net income (FY, 2021)

(13.3m)

EBIT (FY, 2021)

13.6m

Market capitalization (25-May-2022)

3.2b

Closing stock price (25-May-2022)

19.3

Cash (31-Dec-2021)

185.8m

EV

3.3b
Certara's current market capitalization is $3.2 b.
Annual
USDFY, 2019FY, 2020FY, 2021

Revenue

208.5m243.5m286.1m

Revenue growth, %

27%16%17%

Cost of goods sold

79.8m100.8m111.6m

Gross profit

128.7m142.8m174.5m
Quarterly
USDQ1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021

Revenue

57.4m61.1m60.3m66.7m70.1m73.9m

Cost of goods sold

22.2m20.6m23.0m26.0m27.5m28.8m

Gross profit

35.3m40.5m37.3m40.7m42.6m45.2m

Gross profit Margin, %

61%66%62%61%61%61%
Annual
USDFY, 2019FY, 2020FY, 2021

Cash

29.3m271.4m185.8m

Accounts Receivable

49.6m54.1m69.6m

Prepaid Expenses

8.1m19.2m18.5m

Current Assets

87.5m346.6m274.7m
Quarterly
USDQ3, 2020Q1, 2021Q2, 2021Q3, 2021

Cash

29.9m273.0m267.8m416.9m

Accounts Receivable

48.8m54.4m56.6m62.9m

Prepaid Expenses

12.2m19.4m18.6m24.0m

Current Assets

92.8m347.6m344.8m504.8m
Annual
USDFY, 2019FY, 2020FY, 2021

Net Income

(8.9m)(49.4m)(13.3m)

Depreciation and Amortization

41.6m42.8m45.1m

Accounts Payable

10.0m2.4m1.1m

Cash From Operating Activities

38.0m44.8m60.4m
Quarterly
USDQ1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021

Net Income

1.0m3.8m5.1m1.1m(1.8m)(3.6m)

Depreciation and Amortization

10.5m21.1m31.6m10.7m21.4m32.1m

Accounts Payable

1.3m(3.6m)(1.7m)(11.2m)(13.8m)(1.6m)

Cash From Operating Activities

8.8m16.6m32.1m4.9m19.6m39.6m
USDFY, 2019

Debt/Equity

0.8 x

Debt/Assets

0.4 x

Financial Leverage

2.1 x
Show all financial metrics

Certara Operating Metrics

Certara's Enterprise Customers was reported to be 1.6 k in Q3, 2020.
Q3, 2020

Countries

60

Enterprise Customers

1.6 k

Customers (Regulatory Agencies)

17

Biosimulation Software Platforms

4

Certara Acquisitions / Subsidiaries

Company NameDateDeal Size
Integrated Nonclinical Development Solutions, Inc.January 03, 2022$7.08 m
Pinnacle 21October 01, 2021$339.08 m
Insight Medical Writing LimitedJune 07, 2021$15.2 m
Author B.V.March 02, 2021$2.67 m
Analytical LaserApril 12, 2018
BaseCaseFebruary 01, 2018
d3 Medicine Logo d3 MedicineSeptember 07, 2016
XenologiQDecember 01, 2015
SynchrogenixApril 05, 2014
Great Lakes Drug DevelopmentAugust 13, 2013
Show more

Certara Revenue Breakdown

Embed Graph

Certara revenue breakdown by business segment: 69.7% from Services and 30.3% from Software

Certara revenue breakdown by geographic segment: 19.7% from EMEA, 71.8% from Americas and 8.5% from Asia Pac

Certara Cybersecurity Score

Cybersecurity ratingPremium dataset

A

90/100

SecurityScorecard logo

Certara Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Certara Online and Social Media Presence

Embed Graph

Certara News and Updates

Certara Reports Fourth Quarter and Full Year 2021 Financial Results

PRINCETON, N.J., March 01, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the fourth quarter and full year of 2021 and updated guidance for 2022.

Certara Customers Received 90 Percent of US FDA Novel Drug Approvals for 8th Consecutive Year

Asserts Certara’s leadership in advancing the development and approval of new drugs for patients Asserts Certara’s leadership in advancing the development and approval of new drugs for patients

Insights on the Refractive Surgery Devices Global Market to 2027 - Featuring Alcon, Avedro and Certara Among Others

DUBLIN, Jan. 17, 2022 /PRNewswire/ -- The "Refractive Surgery Devices Market Research Report by Product Type, by End-user, by Application, by Region - Global Forecast to 2027 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering. The Global Refractive...

Insights on the Biosimulation Global Market to 2026 - Featuring Certara, Evidera and Gendata Among Others

Dublin, Jan. 06, 2022 (GLOBE NEWSWIRE) -- The "Biosimulation Market Research Report by Product & Service, Delivery Model, End-user, Application, and Region - Global Forecast to 2026 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering. The Global Biosimul…

Certara Announces FDA Renewal and Expansion of Certara’s Biosimulation Software for Reviewing Regulatory Submissions

FDA holds more than 400 Simcyp™ and Phoenix™ software licenses across 12 divisions and offices FDA holds more than 400 Simcyp™ and Phoenix™ software licenses across 12 divisions and offices

USD 4.63 bn growth in Regulatory Affairs Outsourcing Market from 2021 to 2026 | Evolving Opportunities with Certara Inc., Charles River Laboratories International Inc. & Genpact Ltd | 17000+ Technavio Reports

NEW YORK, Dec. 17, 2021 /PRNewswire/ -- The regulatory affairs outsourcing market is fragmented, and the degree of fragmentation will accelerate during the forecast period. Certara Inc., Charles River Laboratories International Inc., Genpact Ltd., Icon Plc, Laboratory Corp. of America...
Show more

Certara Blogs

Essentials of Model-informed Drug Development (MIDD) – Top-down vs. Bottom-up Approaches

How can the latest modeling and simulation technologies accelerate drug discovery and development? We frequently receive questions about why model-informed drug development (MIDD) is so critical to informing the development of safer and more effective new drugs? Indeed, all drug discovery and develo…

British Pharmacology Society:Pharmacology 2021

The post British Pharmacology Society:<br>Pharmacology 2021 appeared first on Certara.

Certara to Participate in Upcoming Investor Conferences

PRINCETON, N.J.— August 31, 2021 — Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in a fireside chat at the following virtual investor conferences: Morgan Stanley 19th Annual Global Healthcare ConferenceDate and Time: Tuesday,…

AMCP Nexus 2021

The post AMCP Nexus 2021 appeared first on Certara.

European Medical Device & Diagnostic Reimbursement & Market AccessVirtual Conference 2021

The post European Medical Device & Diagnostic<br> Reimbursement & Market Access<br>Virtual Conference 2021 appeared first on Certara.

AAPS PharmSci 360 Annual Meeting

The post AAPS PharmSci 360 Annual Meeting appeared first on Certara.
Show more

Certara Frequently Asked Questions

  • When was Certara founded?

    Certara was founded in 2008.

  • Who are Certara key executives?

    Certara's key executives are William Feehery, Steve Sibley and Diana O'Rourke.

  • How many employees does Certara have?

    Certara has 1,054 employees.

  • What is Certara revenue?

    Latest Certara annual revenue is $286.1 m.

  • What is Certara revenue per employee?

    Latest Certara revenue per employee is $271.4 k.

  • Who are Certara competitors?

    Competitors of Certara include Resilience, DrugDev and Schrodinger.

  • Where is Certara headquarters?

    Certara headquarters is located at 100 Overlook Center #101, Princeton.

  • Where are Certara offices?

    Certara has offices in Princeton, Cincinnati, Clayton, Jenkintown and in 26 other locations.

  • How many offices does Certara have?

    Certara has 30 offices.